tesamorelin metabolism: Frequently asked questions

GH is diabetogenic. It stimulates hepatic glucose production and reduces peripheral glucose uptake. If fasting glucose rises above 110 mg/dL or HbA1c increases by more than 0.5%, the options are dose reduction (from 2mg to 1mg daily), insulin sensitisation (metformin or berberine), or discontinuation if the patient has pre-existing diabetes. The COSMIX trial excluded patients with diabetes precisely because the glucose effect, though mild in most patients, becomes problematic in those with impaired beta-cell function. Monitoring fasting glucose every 4 weeks during the first 12 weeks is standard protocol. If glucose trends upward consistently, intervention is required before frank hyperglycaemia develops.

Measure compliance first. The peptide must be refrigerated at 2–8°C after reconstitution, and dosing must be consistent (daily, same time). If storage or administration is correct, the next variable is baseline GH reserve. Patients with severely suppressed endogenous GH production (common in advanced HIV lipodystrophy or age-related GH decline) may have blunted pituitary responsiveness. A baseline IGF-1 test can clarify whether the pituitary is responding. If IGF-1 doesn't increase by at least 100 ng/mL after 4 weeks of tesamorelin, the GHRH receptor may be desensitised or somatotroph cell mass may be reduced. In that case, combination therapy (tesamorelin + a GH secretagogue like ipamorelin) may restore responsiveness.

IGF-1 elevation without fat loss suggests the lipolytic signal is reaching adipocytes but either (1) caloric intake is high enough to replace mobilised fat, or (2) insulin is suppressing HSL activation despite IGF-1 presence. The second scenario occurs in patients with severe insulin resistance. Elevated insulin blocks lipolysis even when IGF-1 is trying to activate it. The solution is insulin sensitisation: metformin 1,000–1,500 mg daily, or berberine 500 mg three times daily, can lower fasting insulin enough to allow IGF-1-driven lipolysis to proceed. The clinical reality is that tesamorelin works best in patients who are metabolically flexible. Those with advanced diabetes or uncontrolled hyperinsulinaemia may need glycaemic control first.

Assume partial potency loss and either discard the vial or accept reduced efficacy for remaining doses. Lyophilised tesamorelin is stable at room temperature before reconstitution, but once mixed with bacteriostatic water, the peptide begins fragmenting at temperatures above 8°C. After 24 hours at 20–25°C, potency drops by an estimated 30–50%. The peptide doesn't become harmful, but it won't produce the expected GH response. There's no way to test potency at home, so the conservative approach is replacement. If replacing isn't immediately feasible, continue dosing from the compromised vial while ordering fresh supply, understanding that the next 5–7 days of injections will be less effective than protocol standard.

Take the dose as soon as you remember, provided it's still at least two hours before your next scheduled injection. Tesamorelin doesn't accumulate in tissue. Each dose is an independent GH pulse. Missing a dose means you lose that day's growth hormone stimulation, but doubling up the next day doesn't compensate and risks excessive GH release that could elevate glucose or cause joint discomfort. If you consistently inject at inconsistent times, you're not harming yourself, but you're reducing protocol efficacy because the peptide works best when it reinforces circadian GH patterns rather than creating random pulses.

Administer the dose anyway. Skipping is worse than suboptimal timing. Elevated insulin and glucose from recent food intake will blunt the GH response by 30–50%, meaning you'll get a smaller growth hormone pulse than fasted administration would produce. The peptide's half-life doesn't change, but receptor activation at the pituitary is suppressed when insulin levels are high. If this happens occasionally, the impact is minimal. Tesamorelin's efficacy is measured across weeks of daily dosing, not single injections. Consistent post-meal administration, however, reduces cumulative GH exposure enough to meaningfully slow visceral fat reduction and lean mass preservation.